Melissa Johnson provides an overview of the CodeBreaK 200 study pitting sotorasib against docetaxel in patients who have received prior treatment for non-small-cell lung cancer with KRAS G12C mutations.

Nab-paclitaxel offers a similar survival benefit to docetaxel when given to previously treated patients with advanced non-small-cell lung cancer, show data from the phase 3 J-AXEL trial.

The anti-PD-1 antibody tislelizumab may improve outcomes relative to docetaxel as a second- or third-line therapy for people with advanced non-small-cell lung cancer, regardless of histology or PD-L1 expression levels, researchers report.

Karim Fizazi describes results from the phase 3 PEACE-1 trial suggesting that the combination of abiraterone, androgen deprivation therapy, and docetaxel could be an option for patients with a new diagnosis of metastatic castration-sensitive prostate cancer.

Combining a PD-1 inhibitor with docetaxel could benefit chemotherapy-naïve men with metastatic castration-resistant prostate cancer, suggest results from two early-phase trials.

Men with metastatic hormone-naïve prostate cancer have improved outcomes with the addition of docetaxel to androgen deprivation therapy irrespective of whether they have high or low burden of disease, indicates an analysis of the STAMPEDE trial.

Women with early-stage breast cancer have a differential response to adjuvant docetaxel therapy according to their BMI, finds a post-hoc analysis of a phase 3 trial.

Long-term analysis of the CHAARTED trial confirms the survival benefit conferred by the addition of docetaxel to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer.

Updated results from the RANGE trial support improved progression-free survival with the addition of ramucirumab to docetaxel in patients with platinum-refractory advanced urothelial carcinoma, but show no significant overall survival benefit.

The author of a linked commentary says that “[a] possible explanation is the respective pharmacodynamics of TTFields and docetaxel.”

There is no survival difference between patients receiving abiraterone acetate plus prednisolone or docetaxel plus prednisolone for the long-term treatment of high-risk locally advanced or metastatic prostate cancer, STAMPEDE data show.

Adding selumetinib to docetaxel does not improve progression-free survival over docetaxel alone in patients with previously treated, advanced, KRAS- mutant non-small-cell lung cancer, phase III trial data show.